نتایج جستجو برای: glucagon receptor antagonist

تعداد نتایج: 618773  

Journal: :American journal of physiology. Endocrinology and metabolism 2008
Viorica Ionut Dan Zheng Darko Stefanovski Richard N Bergman

Exenatide is a long-acting glucagon-like peptide-1 (GLP-1) mimetic used in the treatment of type 2 diabetes. There is increasing evidence that GLP-1 can influence glycemia not only via pancreatic (insulinotropic and glucagon suppression) and gastric-emptying effects, but also via an independent mechanism mediated by portal vein receptors. The aim of our study was to investigate whether exenatid...

Journal: :American journal of physiology. Gastrointestinal and liver physiology 2012
Sara Baldassano Guo-Du Wang Flavia Mulè Jackie D Wood

Glucagon-like peptide-1 (GLP-1) acts at the G protein-coupled receptor, GLP-1R, to stimulate secretion of insulin and to inhibit secretion of glucagon and gastric acid. Involvement in mucosal secretory physiology has received negligible attention. We aimed to study involvement of GLP-1 in mucosal chloride secretion in the small intestine. Ussing chamber methods, in concert with transmural elect...

2017
Eric G. Vajda Douglas Logan Kenneth Lasseter Danielle Armas Diane J. Plotkin JD Pipkin Yong-Xi Li Rong Zhou David Klein Xiaoxiong Wei Stacy Dilzer Lin Zhi Keith B. Marschke

AIM To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of a novel, oral glucagon receptor antagonist, LGD-6972, in healthy subjects and subjects with type 2 diabetes (T2DM). METHODS In the single ascending dose study, LGD-6972 (2-480 mg) was administered to healthy subjects (n = 48) and T2DM subjects (n = 8). In the multiple ascending dose...

Journal: :Proceedings for Annual Meeting of The Japanese Pharmacological Society 2018

Journal: :The Journal of biological chemistry 2015
Cathryn Weston Jing Lu Naichang Li Kerry Barkan Gareth O Richards David J Roberts Timothy M Skerry David Poyner Meenakshi Pardamwar Christopher A Reynolds Simon J Dowell Gary B Willars Graham Ladds

The glucagon and glucagon-like peptide-1 (GLP-1) receptors play important, opposing roles in regulating blood glucose levels. Consequently, these receptors have been identified as targets for novel diabetes treatments. However, drugs acting at the GLP-1 receptor, although having clinical efficacy, have been associated with severe adverse side-effects, and targeting of the glucagon receptor has ...

Journal: :middle east journal of cancer 0
muath mohammed abu hilal school of nursing, hashemite university, az zarqa, jordan

antiemetics are given to cancer patients prior to their chemotherapy sessions to protect them from nausea and vomiting induced by chemotherapy. the responsible health care team member will choose the type of antiemetic required to prevent the patient from developing nausea and vomiting according to the chemotherapy ematogenicity level. current guidelines recommend using a single antiemetic agen...

Journal: :Diabetes 2002
Patrick E MacDonald Anne Marie F Salapatek Michael B Wheeler

Glucagon-like peptide-1 (GLP-1) acts through its G-protein-coupled receptor to enhance glucose-stimulated insulin secretion from pancreatic beta-cells. This is believed to result from modulation of at least two ion channels: ATP-sensitive K(+) (K(ATP)) channels and voltage-dependent Ca(2+) channels. Here, we report that GLP-1 receptor signaling also regulates the activity of beta-cell voltage-d...

Journal: :FEBS letters 2005
Matthew J Mahon Masako Shimada

Parathyroid hormone (PTH) binds to its receptor (PTH 1 receptor, PTH1R) and activates multiple pathways. The PTH1R, a class b GPCR, contains consensus calmodulin-binding motifs. The PTH1R cytoplasmic tail interacts with calmodulin in a calcium-dependent manner via the basic 1-5-8-14 motif. Calcium-dependent calmodulin interactions with the cytoplasmic tails of receptors for PTH 2, vasoactive in...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید